Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSV-Targeted Immunotherapy in Japanese Adults
NCT05989672Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of HSVTI Formulation 2 in herpes simplex virus infection (3 arms), sponsored by GSK. Primary endpoints: Number of Participants Reporting Any Solicited Administration Site Events at Day 29, Number of Participants Reporting Any Solicited Systemic Events at Day 29 and 4 more. Started Aug 2023; status: completed.
02
Drugs
HSVTI Formulation 2
03
Conditions
herpes simplex virus infection
Beyond the preview
Go deeper on NCT05989672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989672.